Alexander Kulesza
Overview
Explore the profile of Alexander Kulesza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niarakis A, Laubenbacher R, An G, Ilan Y, Fisher J, Flobak A, et al.
NPJ Syst Biol Appl
. 2024 Nov;
10(1):141.
PMID: 39616158
Digital twins represent a key technology for precision health. Medical digital twins consist of computational models that represent the health state of individual patients over time, enabling optimal therapeutics and...
2.
Kulesza A, Couty C, Lemarre P, Thalhauser C, Cao Y
J Pharmacokinet Pharmacodyn
. 2024 Jun;
51(6):581-604.
PMID: 38904912
Quantitative predictive modeling of cancer growth, progression, and individual response to therapy is a rapidly growing field. Researchers from mathematical modeling, systems biology, pharmaceutical industry, and regulatory bodies, are collaboratively...
3.
Go N, Arsene S, Faddeenkov I, Galland T, Martis B S, Lefaudeux D, et al.
J Allergy Clin Immunol
. 2024 Feb;
153(5):1330-1343.
PMID: 38369029
Background: The development of atopic dermatitis (AD) drugs is challenged by many disease phenotypes and trial design options, which are hard to explore experimentally. Objective: We aimed to optimize AD...
4.
Arsene S, Pares Y, Tixier E, Granjeon-Noriot S, Martin B, Brueziere L, et al.
Methods Mol Biol
. 2023 Sep;
2716:51-99.
PMID: 37702936
Modeling and simulation (M&S), including in silico (clinical) trials, helps accelerate drug research and development and reduce costs and have coined the term "model-informed drug development (MIDD)." Data-driven, inferential approaches...
5.
Karr J, Malik-Sheriff R, Osborne J, Gonzalez-Parra G, Forgoston E, Bowness R, et al.
Front Syst Biol
. 2023 Mar;
2.
PMID: 36909847
During the COVID-19 pandemic, mathematical modeling of disease transmission has become a cornerstone of key state decisions. To advance the state-of-the-art host viral modeling to handle future pandemics, many scientists...
6.
Arsene S, Couty C, Faddeenkov I, Go N, Granjeon-Noriot S, Smit D, et al.
Nat Commun
. 2022 Apr;
13(1):1980.
PMID: 35418135
Respiratory disease trials are profoundly affected by non-pharmaceutical interventions (NPIs) against COVID-19 because they perturb existing regular patterns of all seasonal viral epidemics. To address trial design with such uncertainty,...
7.
Courcelles E, Boissel J, Massol J, Klingmann I, Kahoul R, Hommel M, et al.
Front Med Technol
. 2022 Mar;
4:810315.
PMID: 35281671
Health technology assessment (HTA) aims to be a systematic, transparent, unbiased synthesis of clinical efficacy, safety, and value of medical products (MPs) to help policymakers, payers, clinicians, and industry to...
8.
Daly S, Weske S, Mravak A, Krstic M, Kulesza A, Antoine R, et al.
J Chem Phys
. 2021 Jul;
154(22):224301.
PMID: 34241235
Electrospray ionization of phenyl argentates formed by transmetalation reactions between phenyl lithium and silver cyanide provides access to the argentate aggregates, [AgPh], which were individually mass-selected for n = 2-8...
9.
Viceconti M, Emili L, Afshari P, Courcelles E, Curreli C, Famaey N, et al.
IEEE J Biomed Health Inform
. 2021 Jun;
25(10):3977-3982.
PMID: 34161248
The term "In Silico Trial" indicates the use of computer modelling and simulation to evaluate the safety and efficacy of a medical product, whether a drug, a medical device, a...
10.
Musuamba F, Skottheim Rusten I, Lesage R, Russo G, Bursi R, Emili L, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jun;
10(8):804-825.
PMID: 34102034
The value of in silico methods in drug development and evaluation has been demonstrated repeatedly and convincingly. While their benefits are now unanimously recognized, international standards for their evaluation, accepted...